Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Five things for pharma marketers to know: Thursday, March 29, 2018
PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs;
Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug
PBMs began by providing a huge service to payers, but in recent years, they’ve begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.
In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit’s recommendation. Is industry warming to ICER?
Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?
March 13, 2018
9:14 pm
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
Azar’s tough assignment: ‘Rocketing down’ drug prices